Glucagon-like peptide-1 (GLP-1) drugs continued to reshape India’s pharmaceutical market in November, delivering some of the strongest monthly brand sales. GLP-1 medicines, originally developed for diabetes, have more recently been prescribed for weight loss, driving a sharp rise in demand for the category.

According to Pharmatrac data, the GLP-1 segment has now crossed ₹1,000 crore in value, led by two injectable weight-loss drugs — Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.

Wegovy, launched in June 2025, saw a sharp pickup in November after Novo Nordisk cut prices by 30–35%. The per-dose cost fell to ₹2,700–₹4,100 from the earlier ₹4,000–₹6,000 range. The impact was immediate: monthly volumes rose from 26,000 units in October to 45,000 units in November, pushing Wegovy’s market sh

See Full Page